A takeout at $105 per share represents a more than 60% premium to the average closing price of the last month.

Wall Street hates the exclusive license to Freenome's liquid screen for colon cancer. Meanwhile, the business roared to $811 million in revenue and a net loss of just $1 million, crushing estimates.

The company's blood-based colon cancer screening tool is likely to fall short of Medicare coverage requirements, which recommend specificity of 90% or above. But it's not so simple.

The business has generated $323 million in cash from operations in the last year, but investors might cut short their celebration if recent and upcoming launches falter.

A look at what to expect when companies report first-quarter 2025 operating results beginning in late April and extending through May.

A refined lipid nanoparticle may deliver a base editing payload into liver cells more safely than its predecessor. But the biggest risk might be commercializing it.

Product costs grew faster than revenue in 2024, but the launch of Cologuard Plus should improve margins this year.

This month I reveal my lessons from the last market bubble and correction, which influences my current strategy. I also beat you over the head as a reminder to avoid FOMO, remain disciplined, and keep your emotions separated from your money.

The business is objectively healthier than ever based on operating efficiency metrics, but several unexpected headwinds will result in weaker than expected growth for 2024.

The two technology-enabled drug developers plan to merge under the Recursion name, stock ticker, and leadership. Things could get messy.

The business is the healthiest it's ever been – and rapidly improving – just as investors begin to worry about the health of the U.S. economy and frothiness of the stock market.

Like many AI-drug discovery platforms, Exscientia has demonstrated little real-world evidence supporting the expensive approach. That could change by the end of 2024.

The cancer diagnostics company reported year-over-year revenue growth of just 6.5% to start 2024 and made heavier investments, which drove key operating metric down.

The base editing pioneer paused development of cardiometabolic candidate VERVE-101 after reporting serious adverse events in a dose escalation study. The side effects were almost certainly related to the drug delivery tool and PCSK9 inhibition, not the base editor itself.

The number of patients eligible for their second or third Cologuard screening will increase from an estimated 1.4 million in 2023 to 2.0 million in 2024. Revenue from rescreens could grow at least 85% from 2022 to 2025.

The Emirati Genome Program ended short of its revenue target, while U.S. curbs on NVIDIA chip exports have ensnarled Oxford Nanopore's flagship instruments. The business remains strong.

Selecta Biosciences, now Cartesian Therapeutics, is a completely different company with a messy share structure. We've decided to replace it with a larger, more investable biotech stock.

The synthetic biology CRO looks certain to boast at least $900 million in cash at the end of 2023. The path to profitability is a little foggier.

The immune tolerance pioneer hopes to transition from a drug developer into a lean, mean, royalty-paying machine. What happens until then?

The multi-omics diagnostics leader is trending in the right direction on nearly every important metric. It'll need to keep the momentum going ahead of multiple important launches.

The single-cell analysis and spatial biology leader had racked up an impressive string of legal wins protecting its patent estate. The latest decision has relatively little impact.

The company plans to focus on SEL-212, which it estimates could reach peak annual sales of over $700 million. It has paused most other development activity in the meantime.

The Cologuard leader raised guidance for full-year 2023 revenue and adjusted EBITDA. This is a high-quality growth stock and we believe investors can feel comfortable paying up now for future growth, but shares are likely overvalued based on expected 2023 or 2024 financial performance.

The BLUE-C study of a next-generation version of Cologuard met all primary endpoints and reduced false positives by 30% compared to the existing product. However, there was no meaningful improvement on precancerous lesion detection.

The genetic diagnostics leader raised full-year 2023 revenue guidance, now expects to achieve positive free cash flow in 2023 instead of 2024, and is on pace to achieve positive full-year 2024 operating income according to our modeling.

The precommercial drug developer has finally deprioritized wholly-owned gene therapy programs. Unfortunately, so have several other drug developers throughout the global landscape.

Initial data from two late-stage studies suggest SEL-212 can be commercially competitive with Krystexxa and its combination formulation. That increases the value of the royalty stream for Selecta Biosciences – or a financing partner

The business grew Screening revenue 30% in 2022 from the year-ago period, but initial full-year 2023 revenue guidance expects the segment to grow "only" 18% at the midpoint. This is likely an underestimate.

The single-cell analysis pioneer ended a frustrating 2022 by launching a new instrument. Although the new Visium platform could re-accelerate growth in 2023, it might mask a bigger problem facing the business stemming from slowing consumables revenue growth.

Solt DB Invest initiates coverage of Centessa Pharmaceuticals, which is the 15th company to receive written coverage.

Solt DB Invest initiates coverage of Exscientia, which is the 14th company to receive written coverage.

Results from the multi-target stool DNA (MT-sDNA) portion of the BLUE-C study in colon cancer screening are expected in early 2023. A disappointing readout could crush the stock's rally, or lead to a short-term pop if the market gets carried away.

A favorable study design suggests a positive outcome is likely for the upcoming phase 3 data readout for SEL-212 in early 2023. Here's what it needs to do to compete with Krystexxa.

Immune tolerance is quietly gaining traction in the global industry thanks to efforts from an emerging crop of private startups. The technology stack of Selecta Biosciences, anchored by ImmTOR-IL and Xork, is one of the best positioned.

Quick updates for Coherus BioSciences, Exact Sciences, Krystal Biotech, and Selecta Biosciences.

Liquid biopsy screening tests for colorectal cancer (colon cancer) remain challenged in the competitive landscape, even with high adherence rates.

Oxford Nanopore is one of the few companies spreading a belief that the cost of biological experimentation should be dropping. It's one of the most important companies enabling the future of living tech.

Management raised full-year 2022 revenue guidance and slashed operating expenses guidance. The new guidance ranges could still be too conservative.

This article explores Solt DB Invest forecast and modeling in greater detail, including current expectations for revenue and profitability ramps.

Solt DB Invest initiates coverage of Exact Sciences, which is the 11th company in our coverage ecosystem. This article explains the competitive landscape in multi-cancer early detection (MCED) diagnostics.

Solt DB Invest initiates coverage of 10x Genomics, the 10th company in our coverage ecosystem. This article reviews the technology platform, upcoming product launch of Visium, and the valuation risk.

Our founder reduced the size of his positions in Certara and 10x Genomics to nearly double his position in AVITA Medical

In relationships, it's important to keep the sex dirty and the fights clean. In DNA sequencing, it would be ideal to keep the samples dirty and the data clean. Oxford Nanopore and nanopore sequencing are the closest to this ideal technology.